Pharsight

Drugs that contain Venetoclax

1. Venclexta patents expiration

VENCLEXTA's oppositions filed in EPO
VENCLEXTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546399 ABBVIE INC Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Jun, 2031

(7 years from now)

US10730873 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Nov, 2031

(7 years from now)

US8722657 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982 ABBVIE INC Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
May, 2030

(6 years from now)

US11369599 ABBVIE INC Melt-extruded solid dispersions containing an apoptosis-inducing agent
May, 2032

(8 years from now)

US10993942 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

US11110087 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

US11413282 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

US9539251 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 15, 2026

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnos...

Dosage: TABLET;ORAL

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents

2. Venclexta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590128 ABBVIE Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 15, 2026

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of aml by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine to adults 75 years or older or having certain comorbidities per a dose ramp-up including an in...

Dosage: TABLET;ORAL

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents